Erythromycin ethylsuccinate

Cadila Pharmaceuticals Limited🇺🇸 United States

FDA Page

Effective Date: Nov 11, 2023
Approval ID: db70798e-5e07-41d6-afe9-82c272bc5cc0
Products: 2 registered
Version: 5

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Quick Stats

Total Products2

Labelers2

Label Sections12

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.